Biomedix Incubator Ltd. (TASE:BMDX) today completed its acquisition of 80% of the Ashkelon Technological Industries (ATI) incubator, which focuses on the life sciences.
In a separate development Biomedix subsidiary ReproMed Ltd., which develops novel preparation procedures for infertility treatments, has signed strategic distribution agreement with RI, which will market the company’s products in the UK and Ireland. Biomedix owns 85% of Meytav Technological Enterprises Innovation Center Ltd., which owns 51% of ReproMed.
Another subsidiary in which Meytav holds a 35% stake, UC Care Ltd., which develops technologies for treatment of the prostate, has obtained financing for a joint project with Apical Instruments Inc., a US manufacturer of minimally invasive surgical instruments.
A third subsidiary in which Meytav owns a 22% stake, Zephyr ProteomiX Ltd., has obtained financing from Israel-United States Binational Industrial Research and Development Foundation (BIRD-F) for a joint project with Donaldson to develop nanocomposite materials with large porosity for cell cultures and separation technologies. Zephyr ProteomiX develops high-throughput screening (HTS)-based microarray products designed to simplify and facilitate the medical laboratory and to improve the quality of patient care. Donaldson makes filters.
Published by Globes [online], Israel business news - www.globes.co.il - on June 28, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007